Experts Warn of Pradaxa Bleeding After More than 4300 FDA Reports

Share Article

The Web’s largest source for information on Pradaxa research, side effects and legal news is available at the Pradaxa Resource Center. Visit http://www.Pradaxa-lawsuits.org

Pradaxa lawsuit
Anyone affected by internal bleeding or the loss of a loved one from Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible.

The Pradaxa Resource Center, a patient advocacy center, is alerting those prescribed the blood thinner Pradaxa that experts have linked it to severe internal bleeding and hundreds of patient deaths.

A federal judge recently ruled that those injured may proceed with lawsuits. Anyone affected by internal bleeding or the loss of a loved one from Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible.

Pradaxa is a popular anticoagulant drug prescribed to stop strokes and blood clots in patients with atrial fibrillation. Although only on the market since October, 2010, the drug has earned over $1 billion for manufacturer Boehringer Ingelheim in the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.

The FDA warned on December 7, 2011, that it was investigating the safety of Pradaxa after receiving more injury or death reports than expected. Although Reuters reported last November that the drug maker admitted to 260 internal bleeding deaths, USA Today reported on August 19th that the FDA actually received 3,781 reports of side effects and 542 deaths among Pradaxa users last year, the most of all medications.

Although all anticoagulants typically carry a risk of internal bleeding, most have a reversal agent available to doctors in emergency. A March 6, 2012 report by the Journal of Neurosurgery detailed a specific case and complaints by doctors that, once Pradaxa causes internal bleeding in a patient, there is very little they can do to stop it.

Due to the number of Pradaxa lawsuits expected, a central court was recently established in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. On July 25th, Judge David Herndon issued an order denying attempts by Boehringer Ingelheim to dismiss Pradaxa bleeding lawsuits.

Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options. Due to the specialized nature of these federal MDL cases, the Pradaxa Resource center only recommends lawyers who are already handling Pradaxa lawsuits.

For more information on the research, warnings, Pradaxa side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
Visit website